Functionality of Albumin in the Context of Hemodialysis

Last updated: August 17, 2024
Sponsor: Universität Duisburg-Essen
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Hemodialysis mode, dialyzer type

Clinical Study ID

NCT06561191
2024_EKEA.29
  • Ages > 18
  • All Genders

Study Summary

Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin.

The aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties.

Our own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. It also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins.

Previous results have mostly been collected in observational studies. As a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constantdialysis treatment regimen

Exclusion

Exclusion Criteria:

  • Age ≤ 18 years

  • Less than three months of regular (3x/week) hemodialysis treatments or lessthan 3 treatments/week

  • Acute or chronic liver disease (Child stage A or higher or fulfillment of theof the Kings College criteria)

  • Infusion of commercial human albumin (e.g. in the context of ascites drainage)in the last three months prior to study inclusion

  • Acute or severe chronic infections

  • Acute tumor disease

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Hemodialysis mode, dialyzer type
Phase:
Study Start date:
August 01, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • University Hospital Essen

    Essen, 45147
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.